Search PubMed⌕ Search

Biomedical subjects

K Murai

Publications and source records attributed to K Murai.

At least 181 records · Page 10Linked to original sources
PubMed1986

[Left ventricular wall motion abnormalities evaluated by factor analysis as compared with Fourier analysis].

Factor analysis was applied to multigated cardiac pool scintigraphy to evaluate its ability to detect left ventricular wall motion abnormalities in 35 patients with old myocardial infarction (MI), and in 12 control cases with normal left ventriculography. All cases were also evaluated by conventional Fourier analysis. In most cases with normal left ventriculography, the ventricular and atrial factors were extracted by factor analysis. In cases with MI, the third factor was obtained in the left ventricle corresponding to wall motion abnormality. Each case was scored according to the coincidence of findings of ventriculography and those of factor analysis or Fourier analysis. Scores were recorded for three items; the existence, location, and degree of asynergy. In cases of MI, the detection rate of asynergy was 94% by factor analysis, 83% by Fourier analysis, and the agreement in respect to location was 71% and 66%, respectively. Factor analysis had higher scores than Fourier analysis, but this was not significant. The interobserver error of factor analysis was less than that of Fourier analysis. Factor analysis can display locations and dynamic motion curves of asynergy, and it is regarded as a useful method for detecting and evaluating left ventricular wall motion abnormalities.

Adult↗
PubMed1985

[Left ventricular function in essential hypertension during isoproterenol infusion].

The left ventricular function of 23 patients with essential hypertension was investigated during infusion of isoproterenol (ISP). These patients consisted of 13 without cardiac hypertrophy (Group NH) and 10 with cardiac hypertrophy (Group HH). Ten normotensive subjects served as normal controls. To assess left ventricular functions, M-mode echocardiograms were recorded at rest and after ISP infusion for 5 minutes (0.005 and 0.01 microgram/kg/min). There were no significant differences in peak negative dD/dt in all groups at rest. But peak negative dD/dt of Group HH significantly decreased after an infusion of 0.005 microgram/kg/min ISP (Group N: 3.43 +/- 0.69, Group NH: 3.15 +/- 0.61, and Group HH: 2.49 +/- 0.48 cm/sec, respectively). The peak negative dD/dt of Group HH was also significantly decreased after a dose of 0.01 microgram/kg/min. Among all patients with hypertension, peak negative dD/dt correlated inversely with left ventricular mass (LVM) after the infusion of ISP (0.005 microgram/kg/min: r = -0.64, p less than 0.001, 0.01 microgram/kg/min: r = -0.68, p less than 0.001). The peak positive dD/dt of Group HH was significantly decreased only when compared with that of Group N at rest (Group N: 3.15 +/- 0.75, Group NH: 3.02 +/- 0.86, and Group HH: 1.92 +/- 0.68 cm/sec, respectively). The difference between the peak positive dD/dt of Group HH and that of Group N was more prominent after the infusion of ISP than at rest. Among all patients with hypertension, the peak positive dD/dt was inversely related to LVM at rest (r = -0.64, p less than 0.002). There was a similar relation between the two indexes after the infusion of ISP. Peak positive dD/dt was related to peak negative dD/dt after a dose of 0.01 microgram/kg/min in Group HH (r = 0.67, p less than 0.05). There was no significant difference in heart rate, change in blood pressure, or total peripheral vascular resistance after the infusion of ISP. It is concluded that diastolic left ventricular dysfunction and latent systolic left ventricular dysfunction are related to increased LVM in Group HH. It seems that after the infusion of ISP severe diastolic left ventricular dysfunction is related to latent systolic left ventricular dysfunction.

Adult↗
PubMed1985

[Clinical evaluation of TMS-19-Q, a new macrolide antibiotic, in otorhinolaryngological infections].

The clinical study for TMS-19-Q.O tablet was performed with multicenter trial. The results obtained were as follows; Final global improvement rating in 332 cases of otorhinolaryngological infections were excellent in 99, good in 142, fair in 40 and poor in 51 and the effective rate was 72.6%. Those of 266 cases with acute infection were excellent in 93 and good in 121 and the effective rate was 80.5%. Optimum daily doses would be 600 mg based on the analysis of 144 cases of the acute infection with sensitive bacteria (MIC: less than or equal to 3.13 micrograms/ml). In acute infection, major causative bacteria were Gram-positive cocci (GPC) indicating the frequency of 72.0% in total isolates and 87.5% in singly isolated cases. In chronic infection, although GPC were also dominant, Gram-negative bacilli were observed in 31.9%. Clinical and bacteriological effective rates of 160 cases of acute infection with single species were 80.6% and 90.3%, and those of 43 cases in chronic infection were 44.2% and 72.7%, respectively. The resistant rates of isolates in acute infection to TMS-19-Q were 13.3% in S. aureus, 7.7% in S. epidermidis, 6.0% in S. pyogenes and 0% in S. pneumoniae. Those in chronic infection were 20.0% in S. aureus and 25.0% in S. epidermidis. Slight adverse reactions, such as skin eruption or gastrointestinal disorders were observed in 14 cases and no severe one was observed. Slight elevation of GOT, GPT, Al-P, BUN, S-Cr. or eosinophil were observed in 12 cases. These results suggest that TMS-19-Q would be useful antibiotic for otorhinolaryngological infections.

Adolescent↗
PubMed1984

Effects of substance P on fluid and amylase secretion in exocrine pancreas of rat and mouse.

The effects of substance P on fluid and amylase secretion were examined in the exocrine pancreas of the rat and the mouse in vivo and in vitro. In the anaesthetised rat, a single intravenous injection of substance P caused an atropine resistant increase in both the basal and caerulein stimulated flow of pancreatic juice and amylase output, but reduced the secretin stimulated pancreatic juice flow. In vitro experiments using superfused mouse pancreatic fragments supported the in vivo result showing that substance P enhanced caerulein stimulated amylase output.

Amylases↗
PubMed1984

Radioimmunoassay of guanabenz, an antihypertensive agent.

Antibodies with a high specificity and sensitivity for [(2,6-dichlorobenzylidene)amino]guanidine acetate (guanabenz, GB), a potent antihypertensive agent, were produced in rabbits immunized with GB conjugated to bovine serum albumin. GB-specific antibodies were detected 6-8 days after the first booster injection and the titer steadily increased over the initial 17-25 weeks of immunization. A high degree of specificity was demonstrated. No metabolite of GB detected in humans or several animal species cross-reacted, even when present in over 100-fold excess. A rapid and convenient radioimmunoassay procedure for GB was designed using these antibodies. Competition between tritiated GB tracer and unlabeled GB for specific antibody binding sites made feasible measurement of as little as 30 pg GB. GB was absorbed rapidly from the gastrointestinal tract and reached a maximum level in the plasma (2.50 +/- 0.45 ng/ml) at 2 h after oral administration (1 mg/kg) to dogs.

Animals↗
PubMed1983

Activities of serum acid ribonuclease in patients with malignant neoplasms or with renal failure.

The activities of serum acid ribonuclease (RNase) were determined in patients with malignant neoplasm or with renal failure. The levels were markedly increased in myelogenous leukemia and renal failure, and only slightly increased in solid cancers, lymphoid malignancies and multiple myeloma. These increases correlated significantly with serum LDH activity in myelogenous leukemia and with creatinine levels in other malignancies or renal failure. The acid RNase content of granulocytes was 22.7-fold higher than that of lymphocytes. The increase of serum acid RNase may suggest an increased granulocyte destruction in myelogenous leukemia and a reduced glomerular filtration in other malignant neoplasms and renal failure.

Acute Kidney Injury↗